1 Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R -targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103:5941–6.
2 Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová, EK, et al. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.Mult Scler. 2018;24(14):1883–91.
3 Cortese I, Ohayon J, Fenton K, Lee CC, Raffeld M, Cowen EW, DiGiovanna JJ, Bielekova B. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847–55.
4 Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, et al. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Mult Scler Relat Disord. 2016;9:36–46.
5 Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. On behalf of the ESMO Guidelines Committee, 2017. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142.